FLT3 blocking peptide

FLT3 Blocking Peptide (Center)

• Gene Names: FLT3; FLK2; STK1; CD135; FLK-2
• Synonyms: FLT3; FLT3 Blocking Peptide (Center); Receptor-type tyrosine-protein kinase FLT3; FL cytokine receptor; Fetal liver kinase-2; FLK-2; Fms-like tyrosine kinase 3; FLT-3; Stem cell tyrosine kinase 1; STK-1; CD135; FLK2; STK1; FLT3 blocking peptide

• Specificity: The synthetic peptide sequence is selected from aa 474-490 of HUMAN FLT3
• Form/Format: Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.
• Sequence Length: 993

• Cellular Location: Membrane; Single-pass type I membrane protein. Endoplasmic reticulum lumen. Note: Constitutively activated mutant forms with internal tandem duplications are less efficiently transported to the cell surface and a significant proportion is retained in an immature form in the endoplasmic reticulum lumen. The activated kinase is rapidly targeted for degradation
• Tissue Location: Detected in bone marrow, in hematopoietic stem cells, in myeloid progenitor cells and in granulocyte/macrophage progenitor cells (at protein level). Detected in bone marrow, liver, thymus, spleen and lymph node, and at low levels in kidney and pancreas. Highly expressed in T-cell leukemia
• Preparation and Storage: Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C.

Related Product Information for FLT3 blocking peptide

Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.

NCBI and Uniprot Product Information

• NCBI GI #: 156630887
• NCBI GeneID: 2322
• UniProt Accession #: P36888; Q13414; A0AVG9; B7ZLT7; B7ZLT8; F5H0A0
• Molecular Weight: 108,378 Da
• NCBI Official Full Name: Receptor-type tyrosine-protein kinase FLT3
• NCBI Official Synonym Full Names: fms related tyrosine kinase 3
• NCBI Official Symbol: FLT3
• NCBI Official Synonym Symbols: FLK2; STK1; CD135; FLK-2
• NCBI Protein Information: receptor-type tyrosine-protein kinase FLT3
• UniProt Protein Name: Receptor-type tyrosine-protein kinase FLT3
• Protein Family: Flt3 receptor-interacting lectin
• UniProt Gene Name: FLT3
• UniProt Synonym Gene Names: CD135; FLK2; STK1; FLK-2; FLT-3; STK-1
• UniProt Entry Name: FLT3_HUMAN

NCBI Description

This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. This receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia. [provided by RefSeq, Jan 2015]

Uniprot Description

FLT3: a receptor tyrosine kinase of the PDGFR family that binds the FL cytokine. FLT3 -/- mice have an impaired developmental capacity of primitive hematopoietic progenitor cells of all lineages with the greatest impact on lymphopoietic precursors. Activating mutations found in one third of cases of acute myeloid leukemia (AML), as well as in acute lymphoblastic leukemia, acute promyelocytic leukemia and myelodysplastic syndrome. Inhibitors: Sutent and PKC412.

Protein type: Protein kinase, tyrosine (receptor); Protein kinase, TK; Membrane protein, integral; EC 2.7.10.1; Oncoprotein; Kinase, protein; TK group; PDGFR family

Chromosomal Location of Human Ortholog: 13q12

Cellular Component: integral to plasma membrane; plasma membrane

Molecular Function: hematopoietin/interferon-class (D200-domain) cytokine receptor activity; protein binding; protein homodimerization activity; transmembrane receptor protein tyrosine kinase activity; vascular endothelial growth factor receptor activity

Biological Process: B cell differentiation; cytokine and chemokine mediated signaling pathway; hemopoiesis; leukocyte homeostasis; lymphocyte proliferation; myeloid progenitor cell differentiation; peptidyl-tyrosine phosphorylation; positive regulation of cell proliferation; positive regulation of MAP kinase activity; positive regulation of MAPKKK cascade; positive regulation of phosphoinositide 3-kinase activity; positive regulation of phosphoinositide 3-kinase cascade; positive regulation of tyrosine phosphorylation of STAT protein; pro-B cell differentiation; protein amino acid autophosphorylation; regulation of apoptosis; transmembrane receptor protein tyrosine kinase signaling pathway

Disease: Leukemia, Acute Lymphoblastic